E-morpholine-4-carboxylic acid (3-{4-[3-chloro-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-amide | 383433-90-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: E-morpholine-4-carboxylic acid (3-{4-[3-chloro-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-amide
• 英文别名: N-[(E)-3-[4-[3-chloro-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-enyl]morpholine-4-carboxamide
• CAS: 383433-90-7
• 化学式: C₂₈H₂₇ClN₆O₃
• 分子量: 531.014
• InChiKey: YZGLJMJTLFVDMY-NSCUHMNNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  38
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  102
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• SELECTIVE ERBB2 INHIBITOR/ANTI-ERBB ANTIBODY COMBINATIONS IN THE TREATMENT OF CANCER
  申请人：Pfizer Products Inc.

  公开号：EP1682176A1

  公开（公告）日：2006-07-26
• [EN] SELECTIVE ERBB2 INHIBITOR/ANTI-ERBB ANTIBODY COMBINATIONS IN THE TREATMENT OF CANCER<br/>[FR] ASSOCIATIONS SELECTIVES D'UN INHIBITEUR DE ERBB2 ET D'UN ANTICORPS ANTI-ERBB DANS LE TRAITEMENT DU CANCER
  申请人：PFIZER PROD INC

  公开号：WO2005044302A1

  公开（公告）日：2005-05-19

  This invention relates to a method of treatment of cancer with a combination of an erbB2 ligand and an antibody, in mammals. More particularly, this invention relates to a method of treating cancer by administering an erbB2 ligand in combination with an erbB antibody. This invention also relates to a kit useful in the treatment of abnormal cell growth in mammals, especially humans.